Ligate Secures Hundreds of Millions in Series D Funding Led by Xinda Kunpeng to Accelerate Global Expansion in Digital Sports Medicine

VCBeat learned that recently, Ligatech, a global platform enterprise in digital sports medicine, has completed a D-round financing of several hundred million yuan. This round of financing was led by Xinda Kunpeng (Shenzhen) Equity Investment Management Co., Ltd., with participation from Guangzhou Hanshi Asset Management Service Co., Ltd., Jian Xin Jin Yuan (Xiamen) Equity Investment Management Co., Ltd., and existing shareholder Legend Capital. HAOYUE CAPITAL served as the exclusive financial advisor for this round of financing.

Ligatech was founded in 2014. The company uses globally leading digital sports medicine as its entry point for diagnosis and treatment, completing a full-process layout from diagnosis + treatment + sports management, covering imaging systems + artificial intelligence, powered devices, implants, and other supporting consumables. The founder has multiple successful entrepreneurial experiences and innovative thinking, with over 30 years of entrepreneurial management and operational experience, deep industry resource accumulation, incubating and establishing several innovative companies in the medical field, and strategically planning for large-scale industry layouts. The company boasts a complete team configuration, with a management team that has rich industry experience spanning technology, R&D, production, and sales. It is also an industry leader in standardized management and financial operations.

With the implementation of policy goals and supporting measures such as "a sports powerhouse" and "Healthy China," along with the increase in per capita income and health awareness, the number of people participating in sports in China, as well as the resulting population with sports injuries, is rapidly rising. The academic status of sports medicine and the number of doctors are also growing quickly. The total number of sports medicine surgeries in China has exceeded one million per year, with an annual growth rate (CAGR) of over 20%, making it the fastest-growing细分赛道 within orthopedics. However, sports medicine surgery in China is still in its early stages of development. According to a Frost & Sullivan report, the penetration rate of arthroscopic surgeries in China was less than 0.1% in 2020. There remains significant room for growth in both the market penetration rate and absolute volume of China's sports medicine sector.

Ligatech focuses on "digital sports medicine" as its strategic core direction, with three major technology platforms in imaging, active devices, and materials and processes, covering over 30 product pipelines. It is the world's only sports medicine enterprise that simultaneously covers four major fields: "imaging systems + AI, active equipment, implants, and accompanying consumables."

The Dual-Plane Imaging System is an innovative orthopedic imaging device independently developed by the company. The technology was initially incubated at Harvard University and MIT, with over 300 SCI publications based on this technology. The team has accumulated more than 10 years of orthopedic research experience and established in-depth cooperative relationships with leading experts and hospitals in the United States. This product addresses issues such as the lack of functional weight-bearing images and dynamic information in traditional orthopedic imaging. Through a fast, low-radiation technical approach, it provides doctors with "3D + full-length + weight-bearing + dynamic" imaging information, offering convenience for orthopedic diagnosis.

Sports medicine is the only细分赛道in orthopedics with a localization rate still below 10%. The centralized procurement of sports medicine will accelerate industry development and expedite the localization process, benefiting leading domestic companies with core technical capabilities, comprehensive product portfolios, strong cost control, and prominent channel advantages.

Ligatech, which owns the exclusive product of dual-plane imaging equipment, has completed the overall layout of all sports medicine consumables and devices after obtaining the first domestically produced artificial ligament registration certificate in the first quarter. The company's overall operational status is continuously improving, with consumables already entering over 2,000 hospitals, and small devices having been installed in more than 200 hospitals. With the catalysis of centralized procurement, Ligatech is expected to lead the domestic companies in breaking through in the sports medicine sector.

Zhao Yanchen, Executive Vice General Manager of Xinda Kunpeng (Shenzhen) Equity Investment Management Co., Ltd.It is reported that with the continuous promotion and popularization of sports, the gradual improvement of people's awareness, and the rapid development of treatment methods, sports medicine is in a golden period of comprehensive and rapid development. Coupled with the trend of domestic substitution in the industry driven by centralized procurement, we believe there are tremendous market opportunities in the industry. As a leading company in the field, Ligatech has a founder with rich experience and resources, a solid team, outstanding R&D capabilities, and platform capabilities. The company has proactively laid out innovative products such as dual-plane dynamic imaging systems and artificial ligaments, providing a complete product solution for the entire diagnosis and treatment process. We hope to accelerate the company’s development through participation in this round of financing, assist in strategic integration, and help the company quickly break through in the sports medicine track dominated by foreign enterprises.

Wang Junfeng, Co-Chief Investment Officer of Legend CapitalIn recent years, sports medicine has become the fastest-growing细分 direction in the field of orthopedics. This industry was almost monopolized by foreign capital in the past, with a strong demand for import substitution. As a leading enterprise in the field of sports medicine, Ligatech has been dedicated to developing and launching several globally scarce innovative products over the years, including the dynamic full-length imaging system, artificial ligaments, etc., providing doctors and patients with full-cycle management and comprehensive ecological solutions. The company already has high知名度 and good clinical foundations in the Chinese market and has also started to enter overseas markets. With significant market opportunities, it is believed that Ligatech has the potential to grow into a globally influential sports medicine supplier in the future.

Yang Zhenjun, Managing Partner of HAOYUE CAPITALIt was expressed that Ligatech is a leading enterprise with forward-looking vision in the industry. The company has an all-star team across all aspects from technology to sales, empowering the group in multiple fields. It has already completed a comprehensive layout including specialized imaging equipment, basic consumables, high-quality implantable consumables, and active devices. The company is highly unique in terms of both its team and products. We are very pleased to accompany the company in this financing round and wish it continued success in the future!